Clinical trials: Resectable Esophageal Squamous Cell Carcinoma
Esophageal Cancer
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous…
- Trial name
- BLESS (NCT06385730)
- Testing
- neoadjuvant anti-PD-1, neoadjuvant anti-PD-1 with LDRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma Resectable
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma
A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone for esophageal cancer.
- Trial name
- NCT01688700
- Testing
- Nimotuzumab combined with paclitaxel and cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced…
- Trial name
- NCT07266493
- Testing
- Chemotherapy （Albumin bound paclitaxel and Carboplatin）
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04506138
- Testing
- Camrelizumab, Paclitaxel for Injection (Albumin Bound), Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
ESCC
Adebrelimab Neoadjuvant Treatment for Resectable ESCC
This is a prospective, phase II, exploratory clinical trial. The study aims to evaluate the efficacy and safety of in combination adebrelimab with nimotuzumab and chemotherapy as neoadjuvant therapy in patients with resectable…
- Trial name
- NCT07388095
- Testing
- Adebrelimab (PD-L1 inhibitor)
- Volunteers
- 22 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Treatment
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Esophageal cancer is a prevalent digestive tract tumor, with around 400,000 new cases and 300,000 deaths globally each year. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously…
- Trial name
- NCT06576973
- Testing
- Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib, Esophagectomy, Collecting samples from participant
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Squamous Cell Carcinoma
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
This is a multi-center, single-arm, phase II clinical study designed to observe and evaluate the effectiveness and safety of adebrelimab combined with albumin paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced…
- Trial name
- NCT06508229
- Testing
- Adebrelimab, albumin paclitaxel, Nedaplatin
- Volunteers
- 65 people
- Sponsor
- Harbin Medical University
Esophageal Cancer
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00069953
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 97 sites in United States
- Volunteers
- 43 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Squamous Cell Carcinoma
Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
This study aims to investigate the safety and efficacy of sintilimab combined with platinum-based chemotherapy in neoadjuvant treatment of potentially resectable esophageal cancer.
- Trial name
- NCT03946969
- Testing
- Sintilimab, Liposomal Paclitaxel + Cisplatin + S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Cancer
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00445861
- Testing
- cetuximab + docetaxel + cisplatin, Treatment level 1, Treatment level 2
- Where
- 2 sites in Switzerland
- Volunteers
- 27 people
- Sponsor
- Swiss Cancer Institute
Esophageal Squamous Cell Carcinoma
Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)
Esophageal squamous cell carcinoma (ESCC), one of the most common subtypes of esophageal cancer, has a poor prognosis and low 5-year overall survival.
- Trial name
- TINES (NCT05603065)
- Testing
- Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Esophageal Cancer
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell…
- Trial name
- NCT06304350
- Testing
- Combination of pembrolizumab and platinum containing dual drugs
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tongji University
Esophageal Squamous Cell Carcinoma
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing…
- Trial name
- NCT06861894
- Testing
- Adebrelimab and nab-paclitaxel and carboplatin, Radiation, standard oesophagectomy
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Zhigang Li
The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a single-arm clinical study to evaluate the efficacy and safety of Cadonilimab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma Locally Advanced Esophageal Squamous…
- Trial name
- NCT05947201
- Testing
- Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Weijia Fang, MD
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery
This phase III trial studies nutritional supplementation with Impact Advanced Recovery to see how well it works compared with standard nutritional supplementation in reducing complications in patients with esophageal cancer that…
- Conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8
- Trial name
- NCT04029857
- Testing
- Nutritional Supplement Drink, Nutritional Supplementation
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death ligand 1(PD-L1) immunotherapy, Adebrelimab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant…
- Trial name
- NCT06225921
- Testing
- Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Esophageal Cancer
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis.
- Trial name
- ECTOP-2005 (NCT05443841)
- Testing
- pleural lavage
- Where
- 11 sites in China
- Volunteers
- 385 people
- Sponsor
- Fudan University
Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study
This was a prospective, multicentre, randomised controlled clinical study to explore the safety and efficacy of esophageal arterial infusion chemotherapy in patients with resectable locally advanced oesophageal cancer, and to…
- Trial name
- NCT05381636
- Testing
- Esophageal arterial infusion chemotherapy, Systemic intravenous chemotherapy
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved…
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT06056336
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guo Xufeng
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT07263919
- Testing
- Cadonilimab (AK104), Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso